BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Research Pipeline
Oral Small-Molecule GLP-1 Drugs Reach Deep Brain Reward Circuits, Pointing Towards Addiction Research Applications
A Nature study published 6 May 2026 found that oral small-molecule GLP-1 receptor agonists, including orforglipron and danuglipron, suppress hedonic feeding in mice by modulating a reward circuit in the central amygdala — a mechanism distinct from the hypothalamic appetite pathways activated by peptide-based GLP-1 drugs. The findings add mechanistic weight to a growing body of evidence linking GLP-1 pharmacology to reduced substance use disorder risk.
08 May 2026
Research Pipeline
MOTS-c: The Mitochondrial Peptide Generating Research Interest in Metabolic Disease and Ageing
MOTS-c is a 16-amino-acid peptide encoded not by the nuclear genome but by the mitochondrial genome, placing it in a distinct class from most research peptides. Growing preclinical data point to roles in glucose metabolism, insulin sensitivity, muscle preservation and β-cell protection, though no approved therapeutic use exists and regulatory status in both the US and UK remains firmly research-only.
08 May 2026